Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 20,000 Shares of Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $89.75, for a total value of $1,795,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Jean Jacques Bienaime also recently made the following trade(s):
- On Saturday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.61, for a total value of $896,100.00.
BioMarin Pharmaceutical Inc. (BMRN) traded up $1.86 during trading on Tuesday, reaching $91.03. The company’s stock had a trading volume of 1,298,980 shares, compared to its average volume of 1,049,140. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91. The firm has a market cap of $15,660.15, a PE ratio of -101.14 and a beta of 1.82. BioMarin Pharmaceutical Inc. has a 12-month low of $80.10 and a 12-month high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. During the same period in the prior year, the firm posted $0.02 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 19.4% compared to the same quarter last year. sell-side analysts expect that BioMarin Pharmaceutical Inc. will post -0.64 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Atlantic Trust Group LLC acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $1,997,000. Americafirst Capital Management LLC acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $702,000. IFM Investors Pty Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $448,000. Piedmont Investment Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $561,000. Finally, California Public Employees Retirement System raised its holdings in shares of BioMarin Pharmaceutical by 1.6% in the 3rd quarter. California Public Employees Retirement System now owns 332,500 shares of the biotechnology company’s stock worth $30,946,000 after buying an additional 5,100 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.
BMRN has been the topic of several recent analyst reports. SunTrust Banks set a $115.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $130.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Sunday, October 29th. Leerink Swann reissued an “outperform” rating and set a $142.00 price target (up from $136.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, October 19th. Jefferies Group reissued a “buy” rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $113.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $112.44.
TRADEMARK VIOLATION NOTICE: “Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 20,000 Shares of Stock” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/insider-selling-biomarin-pharmaceutical-inc-bmrn-ceo-sells-20000-shares-of-stock/1792159.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.